Sanofi/Regeneron's Great ODYSSEY ESCAPE – How Big Is Praluent's Apheresis Benefit?

The full data for Sanofi/Regeneron's ODYSSEY ESCAPE study of their PCSK9 inhibitor Praluent confirm its use in reducing the need for expensive apheresis procedures in severe hypercholesterolemia patients, but the extent of the cost savings is still unclear.

Restricted by cholesterol as a confined person behind prison bars made of clogged artery and atherosclerosis disease arteries as a medical concept with blood cells that is blocked by plaque buildup.
• Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc. have strengthened the case for using their PCSK9 inhibitor Praluent (alirocumab) to reduce or even eliminate the need for expensive and cumbersome apheresis procedures in patients with heterozygous familial hypercholesterolemia (HeFH) with the presentation of the full results of their ODYSSEY ESCAPE study during a Hotline session at the European Society of Cardiology meeting in Rome this weekend. The data have simultaneously been published in the European Heart Journal.

Both the marketed PCSK9 inhibitors, Praluent and Amgen Inc.'s Repatha (evolocumab), have struggled to gain sales traction in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe

 

A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?    

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By 

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.